Bio-techne layoffs, on the record
Every job cut, severance charge and restructuring Bio-techne reported in its annual reports, 2024 to 2026, quoted from the filings. Headcount went from approximately 3,100 to approximately 3,000.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2024 | approximately 3,100 | June 30, 2024 |
| 10-K for 2025 | approximately 3,100 | June 30, 2025 |
| 10-K for 2026 | approximately 3,000 | June 30, 2026 |
Job cuts, severance and restructuring
Our summaryAnnounced an enterprise-wide restructuring focused on recovering operating margins, optimizing the distribution footprint, and enhancing organizational efficiency, affecting about 4% of the global workforce.
Word for word“In the second quarter of fiscal 2024, the Company announced enterprise-wide restructuring focused on recovering operating margins, optimizing our distribution footprint, and enhancing our organization efficiency.” 10-K for 2024
Our summaryRestructuring actions included employee severance, asset-related and other charges, and impairment of assets held-for-sale in the Protein Sciences segment, with the disposal group classified as held-for-sale.
Word for word“During the 45 Table of Contents second quarter of fiscal 2024, as part of restructuring actions, certain assets and liabilities associated with a disposal group in our Protein Sciences segment were classified as held-for-sale as of December 31, 2023.” 10-K for 2024
Our summaryRestructuring actions under the fiscal 2024 restructuring program in the Protein Sciences segment, with a disposal group classified as held-for-sale as of December 31, 2023.
Word for word“During the second quarter of fiscal 2024, as part of restructuring actions, certain assets and liabilities associated with a disposal group in our Protein Sciences segment were classified as held-for-sale as of December 31, 2023.” 10-K for 2025
Our summaryRestructuring actions in the fourth quarter of fiscal 2025 that classified a disposal group in the Diagnostics and Spatial Biology segment as held-for-sale.
Word for word“During the fourth quarter of fiscal 2025, as part of restructuring actions, certain assets and liabilities associated with a disposal group in our Diagnostics and Spatial Biology segment were classified as held-for-sale as of May 31, 2025.” 10-K for 2025
Our summaryRestructuring and restructuring-related costs were recorded, which the filing describes as including reducing overhead and consolidating facilities.
Word for word“Restructuring and restructuring-related costs 28,231 12,245 3,829 ” 10-K for 2025
Our summaryThe filing describes restructuring actions as generally including employee-related severance charges, contract termination costs, and asset impairments.
Word for word“Restructuring actions generally include significant actions involving employee-related severance charges, contract termination costs, and impairments and disposals of assets associated with such actions.” 10-K for 2025
| Fiscal year ended | Restructuring charges | Cash paid for restructuring |
|---|---|---|
| 2018-06-30 | $376,000 | — |
| 2020-06-30 | $87,000 | — |
| 2021-06-30 | $142,000 | — |
| 2022-06-30 | $1.6 million | $1.1 million |
| 2023-06-30 | $3.8 million | — |
| 2024-06-30 | $12.2 million | $7.7 million |
Bio-techne has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Bio-techne’s annual reports (10-K for 2026, 10-K for 2025, 10-K for 2024) and the financial data it files with the SEC, as of 2026-08-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.